Design and synthesis of novel imidazo[4,5-b]pyridine based compounds as potent anticancer agents with CDK9 inhibitory activity

Add time:08/13/2019    Source:sciencedirect.com

New imidazo[4,5-b]pyridine derivatives were designed, synthesized and screened for their anticancer activity against breast (MCF-7) and colon (HCT116) cancer cell lines. Nine compounds (I, II, IIIa, IIIb, IV, VI, VIIa, VIII, IX) showed significant activity against MCF-7, while six compounds (I, VIIc, VIIe, VIIf, VIII, IX) elicited a remarkable activity against HCT116. Compounds showing significant anticancer activity revealed remarkable CDK9 inhibitory potential (IC50 = 0.63–1.32 μM) relative to sorafenib (IC50 = 0.76 μM). Moreover, a molecular docking study was performed to illustrate the binding mode of the most active compounds in the active site of CDK9 where it revealed superior binding affinity relative to the natural ligand (T3C).

We also recommend Trading Suppliers and Manufacturers of 3-(3H-imidazo[4,5-b]pyridin-2-yl)benzenamine (cas 116489-65-7). Pls Click Website Link as below: cas 116489-65-7 suppliers

Prev:Effect of acid modification of kaolin and metakaolin on Brønsted acidity and catalytic properties in the synthesis of octahydro-2H-chromen-4-ol from vanillin and isopulegol
Next:MicroRNA regulation of DNA repair gene expression in 4-aminobiphenyl-treated HepG2 cells)